Ethical Recruiters

We specialize in Director, VP, C-Suite, and Board-Level talent acquisition for startup to mid-sized biotech & pharmaceutical organizations.

[Ethical Recruiters @Ethical421]

Wishing you a very Merry Christmas filled with the warmth of loved ones, the comfort of home, and the quiet joy of the season.

[SoaringMe @SoaringMeTweets]

SoaringME The Ultimate Guide to Successful Job Searching https://t.co/XE7sUP0QHh #Amazon #Jobs

[Michael Miller @MLMiller421]

The inability to accept responsibility is a very undesirable trait in anyone who an employer might hire. It can be an indication of a personality disorder, particularly those in Cluster B. But, even if it’s only due to anxiety, depression, or a general personality trait, it’s a mistake to hire. They likely will blame others, disrupt team dynamics, hinder problem-solving, take extra time to manage, and more. This is why interviewers ask about a candidate’s weakness, a time they received criticism, what their biggest mistake was, etc.

[SoaringMe @SoaringMeTweets]

SoaringME The Ultimate Guide to Successful Job Searching https://t.co/mImTeqz8VV

[Chris Harvey @ChrisHarveyEsq]

In just 3 years, down rounds went from 2-4% in 2021 to:
• Series Seed: 24%
• Series A: 20%
• Series B: 21%
• Series C: 29%*
• Series D+: 37%

*Series C saw the most dramatic leap (7.8% → 29.3% in two years).

Data: @CooleyLLP Q4 2024 Venture Financing Report

[BioSpace @biospace]

Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options in inflammatory bowel disease, atopic dermatitis, myasthenia gravis and more.

#biopharma #immunology #biospace
https://t.co/IzAUcL9bhC

[FiercePharma @FiercePharma]

Moderna trims digital team, lays off employees as chief information officer departs https://t.co/TrxBG0oWVR

[Endpoints News @endpts]

Kojin Therapeutics, a startup attempting to develop new treatments using programmed cell death, announced Thursday it's shutting down from lack of investor interest.
https://t.co/WpNrb0Fk2X

[FiercePharma @FiercePharma]

Bain throws down $3.3B to acquire Japan's Mitsubishi Tanabe Pharma https://t.co/7cJedsjrwR

[BioSpace @biospace]

BioSpace recaps 2024’s top venture capital rounds in biopharma, from Xaira Therapeutics’ blockbuster $1B raise to back-to-back series from obesity-focused Metsera that totaled more than $500M in a space that has garnered more than a fivefold increase in VC dollars this year.
https://t.co/QIjJvIkvFO

[BioSpace @biospace]

Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine pipelines.

#biopharma #JPM2025 #obesity #vaccines #biospace
https://t.co/BdE148azJ0

[FiercePharma @FiercePharma]

JPM25, Day 1: Pfizer CEO discusses plan to overcome $17B 'LOE wave' https://t.co/yc0WpAVpWR

[BioSpace @biospace]

On the heels of an FDA approval for its monoclonal antibody Bizengri, Merus will generate three novel cancer-targeting antibodies that it will pass over to Biohaven to link into antibody drug-conjugates.

#FDA #pharma #biospace
https://t.co/Euzrnm6HrW

[Endpoints News @endpts]

BREAKING: J&J is acquiring Intra-Cellular Therapies for $14.6 billion in the biggest biotech M&A transaction since 2023.
https://t.co/1WUlLMPBed

[St. Louis Fed @stlouisfed]

Fewer job vacancies are being filled by hiring the unemployed and more are being filled by “poaching” workers from other firms. Go to the FRED Blog for @BLS_gov data and recent research that explains the new shape of the labor market https://t.co/u9SWJ8me72

[BioSpace @biospace]

Initial rounds of VC financing totaled $7.7 billion over 137 deals for biopharma in 2024, compared to $3.8 billion over 156 deals in 2023.

#venturecapital #biopharma #biospace
https://t.co/CrkfUHZDJ3

[FiercePharma @FiercePharma]

After two rejections, FDA approves Mesoblast's first-of-its-kind cell therapy https://t.co/psxm32BiOf

[BioSpace @biospace]

Vertex Pharmaceuticals’ investigational non-opioid analgesic suzetrigine failed to outperform placebo. Investors voiced their concerns as the company’s share price fell 13% in premarket trading.

#pharma #biospace
https://t.co/sHgkNDxpWW

[Bertrand Delsuc @BertrandBio]

Edgewise Therapeutics $EWTX Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker) - https://t.co/s1iYTSp8AM

[FirstWord Pharma @fwpharma]

Viridian sees success in second pivotal study for thyroid eye disease $VRDN https://t.co/fjCoTfjM6u